Alpha‐lipoic acid for diabetic peripheral neuropathy
References
Additional references
Abuaisha BB, Costanzi JB, Boulton AJ. Acupuncture for the treatment of chronic painful peripheral diabetic neuropathy: a long‐term study. Diabetes Research and Clinical Practice 1998;39(2):115‐21.
Agrawal Y, Carey JP, Della Santina CC, Schubert MC, Minor LB. Diabetes, vestibular dysfunction, and falls: analyses from the National Health and Nutrition Examination Survey. Otology & Neurotology 2010;31(9):1445‐50. [DOI: 10.1097/MAO.0b013e3181f2f035.]
Allen R, Sharma U, Barlas S. Clinical experience with desvenlafaxine in treatment of pain associated with diabetic peripheral neuropathy. Journal of Pain Research 2014;7:339‐51.
Amin N, Doupis J. Diabetic foot disease: From the evaluation of the "foot at risk" to the novel diabetic ulcer treatment modalities. World Journal of Diabetes 2016;7(7):153‐64. [DOI: 10.4239/wjd.v7.i7.153.]
Bastyr EJ, Price KL, Bril V, MBBQ Study Group. Development and validity testing of the neuropathy total symptom score‐6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy. Clinical Therapeutics 2005;27(8):1278‐94.
Boulton AJM, Gries FA, Jervell JA. Guidelines for the diagnosis and outpatient management diabetic peripheral neuropathy. Diabetic Medicine 1998;15(6):508‐14.
Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, et al. American Diabetes Association. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005;28(4):956‐62. [PUBMED: 15793206]
Bredfeldt C, Altschuler A, Adams AS, Ports J, Bayliss E. Patient reported outcomes for diabetic peripheral neuropathy. Journal of Diabetes and Its Complications 2015;29(8):1112‐8.
Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54(6):1615–25.
Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurology 2012;11(6):521‐34. [DOI: 10.1016/S1474‐4422(12)70065‐0]
Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database of Systematic Reviews 2012, Issue 6. [DOI: 10.1002/14651858.CD007543.pub2]
Chalk C, Benstead TJ, Moore F. Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD004572.pub2]
Challapalli V, Tremont‐Lukats IW, McNicol ED, Lau J, Carr DB. Systemic administration of local anaesthetic agents to relieve neuropathic pain. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD003345.pub2]
Chen W, Zhang Y, Li X, Yang G, Liu JP. Chinese herbal medicine for diabetic peripheral neuropathy. Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: 10.1002/14651858.CD007796.pub3]
Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, et al. The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus. New England Journal of Medicine 1993;329(14):977‐86.
Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. New England Journal of Medicine 2009;360(2):129‐39.
Edwards JL, Vincent AM Cheng HT, Feldman EL. Diabetic neuropathy: mechanisms to management. Pharmacology & Therapeutics 2008;120(1):1‐34. [DOI: 10.1016/j.pharmthera.2008.05.005]
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315(7109):629‐34.
Feldman EL, Stevens MJ, Greene DA. Pathogenesis of diabetic neuropathy. Clinical Neuroscience 1997;4(6):365–70.
Feldman E. Epidemiology and classification of diabetic neuropathy. UpToDate®. Availble from www.uptodate.com/contents/epidemiology‐an Available atd‐classification‐of‐diabetic‐neuropathy (accessed 17 February 2016).
Harris M, Eastman R, Cowie C. Symptoms of sensory neuropathy in adults with NIDDM in the US population. Diabetes Care 1993;16(11):1446–52.
Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. Available from www.cochrane‐handbook.org.
Khanna S, Roy S, Packer L, Sen CK. Cytokine‐induced glucose uptake in skeletal muscle: redox regulation and the role of alpha‐lipoic acid. American Journal of Physiology 1999;276(5 Pt 2):R1327‐33.
Kim PJ, Steinberg JS. Complications of the diabetic foot. Endocrinology and Metabolism Clinics of North America 2013;42(4):833‐47. [DOI: 10.1016/j.ecl.2013.08.002]
Kolm‐Litty V, Sauer U, Nerlich A, Lehmann R, Schleicher ED. High glucose‐induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. Journal of Clinical Investigation 1998;101(1):160‐9.
Low PA, Nickander KK, Tritschler HJ. The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Diabetes 1997;46(Suppl 2):S38‐42.
Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD007115.pub3]
Mallik S, Kallis C, Lunn MPT, Smith AG. Gangliosides for the treatment of diabetic peripheral neuropathy. Cochrane Database of Systematic Reviews 2014, Issue 3. [DOI: 10.1002/14651858.CD011028]
Marangon K, Devaraj S, Tirosh O, Packer L, Jialal I. Comparison of the effect of alpha‐lipoic acid and alpha‐tocopherol supplementation on measures of oxidative stress. Free Radical Biology & Medicine 1999;27(9‐10):1114‐21.
Merkies IS, van Nes SI, Hanna K, Hughes RA, Deng C. Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance. Journal of Neurology, Neurosurgery and Psychiatry 2010;81(11):1194‐9.
Merkies ISJ, Lawo JP, Edelman JM, De Bleecker JL, Sommer C, Robberecht W, et al. PRIMA trial investigators. Minimum clinically important difference analysis confirms the efficacy of IgPro10 in CIDP: the PRIMA trial. Journal of the Peripheral Nervous System: JPNS 2017;22(2):149‐52.
Naderi Nabi B, Sedighinejad A, Haghighi M, Biazar G, Hashemi M, Haddadi S, et al. Comparison of transcutaneous electrical nerve stimulation and pulsed radiofrequency sympathectomy for treating painful diabetic neuropathy. Anesthesiology and Pain Medicine 2015;5(5):e29280. [DOI: 10.5812/aapm.29280]
NCD Risk Factor Collaboration (NCD‐RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population‐based studies with 4.4 million participants. Lancet 2016;387(10027):1513‐30. [DOI: 10.1016/S0140‐6736(16)00618‐8]
Packer L, Witt EH, Tritschler HJ. Alpha‐lipoic acid as a biological antioxidant. Free Radical Biology & Medicine 1995;19(2):227‐50.
Petersen Shay K, Moreau RF, Smith EJ, Hagen TM. Is alpha‐lipoic acid a scavenger of reactive oxygen species in vivo? Evidence for its initiation of stress signaling pathways that promote endogenous antioxidant capacity. IUBMB Life 2008;60(6):362‐7. [DOI: 10.1002/iub.40]
Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (3rd and last part). Diabete & Metabolisme 1977;3(4):245‐56.
Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Rochette L, Ghibu S, Muresan A, Vergely C. Alpha‐lipoic acid: molecular mechanisms and therapeutic potential in diabetes. Canadian Journal of Physiology and Pharmacology 2015;93(12):1021‐7.
Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD005454.pub2]
Snedecor SJ, Sudharshan L, Cappelleri JC, Sadosky A, Mehta S, Botteman M. Systematic review and meta‐analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Practice 2014;14(2):167‐84.
Streeper RS, Henriksen EJ, Jacob S, Hokama JY, Fogt DL, Tritschler HJ. Differential effects of lipoic acid stereoisomers on glucose metabolism in insulin‐resistant skeletal muscle. American Journal of Physiology 1997;273(1 Pt 1):E185‐91.
Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010;33(10):2285‐93.
Tesfaye S, Vileikyte L, Rayman G, Sindrup SH, Perkins BA, Baconja M, et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes/Metabolism Research and Reviews 2011;27(7):629‐38. [DOI: 10.1007/BF00400697]
Uehara K, Yamagishi S, Otsuki S, Chin S, Yagihashi S. Effects of polyol pathway hyperactivity on protein kinase C activity, nociceptive peptide expression, and neuronal structure in dorsal root ganglia in diabetic mice. Diabetes 2004;53(12):3239–47.
Vinik AI, Mehrabyan A. Diabetic neuropathies. Medical Clinics of North America 2004;88(4):947‐99.
Wang Y, Schmeichel AM, Iida H, Schmelzer JD, Low PA. Enhanced inflammatory response via activation of NF‐kappaB in acute experimental diabetic neuropathy subjected to ischemia reperfusion injury. Journal of the Neurological Sciences 2006;247(1):47‐52.
World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus (WHO/NCD/NCS/99.2). Geneva: World Health Organization. http://apps.who.int/iris/bitstream/10665/66040/1/WHO_NCD_NCS_99.2.pdf1999. [WHO/NCD/NCS/99.2]
World Health Organization. Global Report on Diabetes. 2016. www.who.int/diabetes/global‐report/en/ (accessed 22 May 2017).
Xu Q, Pan J, Yu J, Liu X, Liu L, Zuo X, et al. Meta‐analysis of methylcobalamin alone and in combination with lipoic acid in patients with diabetic peripheral neuropathy. Diabetes Research and Clinical Practice 2013;101(2):99‐105. [DOI: 10.1016/j.diabres.2013.03.033]
Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993;36(2):150‐4.
Zhang C, Ma YX, Yan Y. Clinical effects of acupuncture for diabetic peripheral neuropathy. Chung i Tsa Chih Ying Wen Pan [Journal of Traditional Chinese Medicine] 2010;30(1):13‐4.
Ziegler D. Treatment of diabetic polyneuropathy: update. 2006. Annals of the New York Academy of Sciences 2006;1084:250–66.
